IMPORTANCE Dietary modification remains key to successful weight loss. Yet, no one dietary strategy is consistently superior to others for the general population. Previous research suggests genotype or insulin-glucose dynamics may modify the effects of diets.
O besity is a 21st-century major public health challenge. 1, 2 Among many strategies studied for weight loss, a common contrast has been low-fat diets vs lowcarbohydrate diets. [3] [4] [5] Most diet trials have reported modest (ie, <5%) mean weight loss after 12 months and negligible mean weight loss differences between diet groups. 6 In contrast, individual weight losses have varied widely within diet groups in these studies, ranging from approximately 25 kg lost to approximately 5 kg gained. [3] [4] [5] The substantial variability of weight loss response suggests some strategies may work better for some individuals than others, and that no one diet should be recommended universally. 7 Yet, interindividual differences in response to diet are poorly understood. Some studies have reported that genotype variation could predispose individuals to differential weight loss that varies by diet type. 8, 9 In a preliminary retrospective study, a 3-fold difference was observed in 12-month weight loss for initially overweight women who were determined to have been appropriately matched (mean weight loss of 6 kg) vs mismatched (mean weight loss of 2 kg) to a low-fat or low-carbohydrate diet based on multilocus genotype patterns with singlenucleotide polymorphisms (SNPs) from 3 genes (PPARG, ADRB2, and FABP2) relevant to fat and carbohydrate metabolism (a putative low-fat-responsive genotype and a lowcarbohydrate-responsive genotype). The participants with the low-fat-responsive genotype were observed to lose more weight when assigned to a low-fat diet than those assigned to a low-carbohydrate diet, and vice versa for those with the low-carbohydrate-responsive genotype. 9, 10 Similarly, several studies [11] [12] [13] [14] have reported that baseline insulin dynamics may explain differential weight loss success obtained via a low-fat diet vs a low-carbohydrate diet. For example, individuals with greater insulin resistance may have better success with low-carbohydrate diets due to the decreased demand on insulin to clear a lower amount of dietary carbohydrate delivered to the circulation. However, these studies were limited by relatively small sample sizes or post hoc analyses of the results. The primary objective of the Diet Intervention Examining The Factors Interacting with Treatment Success (DIETFITS) study was to test whether (1) a set of 3 SNP genotype patterns or (2) baseline differences in insulin secretion (the blood insulin concentration at 30 minutes after a glucose challenge; INS-30), 12, 13 or both, predisposed individuals to differential success in 12-month weight change while on a low-fat diet vs a low-carbohydrate diet.
Methods
The Stanford University human subjects committee approved the study. All study participants provided written informed consent.
Study Design
This single-site, parallel-group, weight loss diet trial randomized individuals to a healthy low-fat diet or a healthy The first primary hypothesis was that there is a significant diet × genotype pattern interaction for weight loss. The second primary hypothesis was that there is a significant diet × insulin secretion interaction for weight loss. Secondary outcomes included anthropometric measures, plasma lipid levels, insulin and glucose levels, and blood pressure levels. The protocol update and statistical analysis plan are included in Supplement 1 and the full study protocol was published previously 10 (the protocol included details regarding blood sampling, storage, and specific laboratory assays).
Participants
We aimed to recruit 600 adults from the Stanford and San Francisco Bay areas of California using media advertisements and email lists from previous recruitment for nutrition studies conducted by our laboratory group. We considered men and premenopausal women aged 18 to 50 years with a body mass index (calculated as weight in kilograms divided by height in meters squared) of 28 to 40. The major criteria for exclusion were having uncontrolled hypertension or metabolic disease; diabetes; cancer; heart, renal, or liver disease; and being pregnant or lactating. Individuals were excluded if taking hypoglycemic, lipidlowering, antihypertensive, psychiatric, or other medications known to affect body weight or energy expenditure. Any medication type not noted was allowed if the individual had been stable while taking such medication for at least 3 months prior to baseline data collection.
Randomization to a healthy low-fat diet or a healthy low-carbohydrate diet was performed using an allocation sequence determined by computerized random-number generation (Blockrand in R version 3.4.0; R Project for Statistical Computing) in block sizes of 8 (with 4 individuals going to each diet) by a statistician not involved in intervention delivery or data collection. Participants did not learn of their diet group assignment until they completed all baseline measures and attended their first intervention class ( Figure 1) .
The original study design was a 2 × 2 factorial design (diet × genotype-pattern matching). However, near the onset of the study, the initial funding was more than doubled, allowing for a 50% increase in sample size, the addition of a second primary hypothesis for the assessment of a diet × insulin secretion interaction, and an expanded set of measurements. To test for both primary hypotheses, the study was changed to a simple parallel group design with testing for 2 interactions (described in further detail in eAppendix 1 in Supplement 2).
Weight Loss Intervention
The protocol included a 1-month run-in period during which participants were instructed to maintain their habitual diet, physical activity level, and body weight. The intervention involved 22 instructional sessions held over 12 months in diet-specific groups of approximately 17 participants per class. Sessions were held weekly for 8 weeks, then every 2 weeks for 2 months, then every 3 weeks until the sixth month, and monthly thereafter. Classes were led by 5 registered dietitian health educators who each taught 1 healthy low-fat class and 1 healthy low-carbohydrate class per cohort. Dietitians were blinded to all laboratory measures and genotype.
The dietary interventions were described previously. 10 Briefly, the main goals were to achieve maximal differentiation in intake of fats and carbohydrates between the 2 diet groups while otherwise maintaining equal treatment intensity and an emphasis on high-quality foods and beverages. Thus, participants were instructed to reduce intake of total fat or digestible carbohydrates to 20 g/d during the first 8 weeks. Higher priorities for reduction were given to specific foods and food groups that derived their energy content primarily from fats or carbohydrates. For example, the reduction of edible oils, fatty meats, whole-fat dairy, and nuts was prioritized for the healthy low-fat group, whereas the reduction of cereals, grains, rice, starchy vegetables, and legumes was prioritized for the healthy low-carbohydrate group. Then individuals slowly added fats or carbohydrates back to their diets in increments of 5 to 15 g/d per week until they reached the lowest level of intake they believed could be maintained indefinitely. No explicit instructions for energy (kilocalories) restriction were given. Both diet groups were instructed to (1) maximize vegetable intake; (2) minimize intake of added sugars, refined flours, and trans fats; and (3) focus on whole foods that were minimally processed, nutrient dense, and prepared at home whenever possible. Other components of the emphasis on high-quality food for both diet groups are described elsewhere. 10 Participants were encouraged to follow current physical activity recommendations. 15 Health educators emphasized emotional awareness and behavior modification to support dietary adherence and weight loss. Behavioral modification strategies included empirically supported principles of selfregulatory behavior change (eg, goal setting, self-efficacy building, supportive environments, and relapse prevention) based on social cognitive theory and the transtheoretical model.
10,16-18
Outcome Measurements
All data were collected at baseline and at months 3, 6, and 12 for all cohorts unless noted otherwise. Staff who measured outcomes were blinded to diet assignment, genotype pattern, INS-30, and diet assignment. Dietary intake at each time point was assessed using 3 unannounced 24-hour multiple-pass recall interviews (2 on weekdays and 1 on a weekend day).
19
Total energy expenditure was assessed using the Stanford Seven-Day Physical Activity Recall questionnaire. 20 Both the dietary intake and physical activity recall were selfreported measures. Weight was measured by digital scale at the Stanford Clinical Translational Research Unit and 12-month weight change was the primary outcome.
Genotype pattern and insulin secretion were assessed for interaction testing. The Affymetrix UK Biobank Axiom microarray was used for analysis of 820 967 SNPs and insertions or deletions. The array included 2 of the SNPs from the original study design: PPARG (rs1801282) and ADRB2 (rs1042714).
FABP2 (rs1799883) was imputed with an imputation quality score (r 2 = 0.99). Additional details appear in eAppendix 2 in Supplement 2. The 3 SNP multilocus genotype patterns have been explored previously.
9
Of 27 possible 3-locus genotypes that could arise from the combination of the 3 SNPs, 15 were observed with 1% or greater genotype frequency in previously studied samples of adults. The multilocus genotypes were grouped into those predicted to be more sensitive to fat (low-fat genotype; patterns 1-5), more sensitive to carbohydrates (lowcarbohydrate genotype; patterns [6] [7] [8] [9] [10] [11] [12] [13] [14] , or sensitive to neither genotype (pattern 15). Additional details are available in eAppendix 3 in Supplement 2.
Before randomization and at months 6 and 12, each participant completed an oral glucose tolerance test of 75 g. This included measurement of insulin concentration 30 minutes after glucose consumption (ie, INS-30, which is a proxy measure of insulin secretion). 10, 21, 22 When this study was first designed, insulin sensitivity was to be measured and used as a predictor of differential weight loss success. After the study was initiated, reports were published 12, 13, 23, 24 indicating INS-30 was a successful predictor of weight loss in the context of low-carbohydrate diets or similar diets. There also was evidence 25 that early-phase insulin secretion differed markedly between diets that were similar to those tested in the DIETFITS study. Prior to examining any data, we modified the primary hypothesis of our study and tested baseline INS-30 rather than a measure of insulin sensitivity as the putative effect modifier. No other glucose or insulin variables were tested for effect modification. A set of related secondary outcomes was assessed. Concentrations of plasma lipids, glucose, and insulin were measured in fasting samples, waist circumference was assessed by measuring tape, blood pressure was measured via automated device, and all of these were assessed using standard assessment techniques. 10 Body composition was assessed by dual-energy x-ray absorptiometry and both respiratory exchange ratio (bounded by 0.7 [using solely fat for fuel] and 1.0 [using solely glucose for fuel]) and resting energy expenditure were assessed by metabolic cart (ie, measures respiratory exchange of oxygen and carbon dioxide while a participant is supine and resting) at baseline and at months 6 and 12 in cohorts 2 through 5. Adequate funding became available for dual-energy x-ray absorptiometry, respiratory exchange ratio, and resting energy expenditure only after cohort 1 was enrolled. The metabolic syndrome was determined using Adult Treatment Panel III guidelines from the National Cholesterol Education Program. 26 
Statistical Analysis
Based on the original study design, assuming 100 participants in each of the 4 relevant groups (genotype and dietary assignment), and normally distributed values of weight change at 12 months, there was 80% power to detect clinically meaningful differences in treatment effect by genotype (eg, whether dietary assignment had an effect on weight change at 12 months except for those assigned to the lowcarbohydrate diet who have the low-carbohydrate genotype because such individuals lose 3.2 kg on average). This calculation was based on simulations, and assumed a 2-sided Wald test conducted at the .05 level of significance.
Under similar assumptions regarding the statistical testing and type I error, and assuming a sample size of only 400 participants (200 in each treatment group), there was greater than 80% power to detect differences in the treatment effect with insulin secretion, including for example, if for every 1-unit increase in insulin secretion, weight loss at 12 months increases by 0.8 lb (0.36 kg). These power calculations were performed a priori for the originally planned sample size of 400. As described in greater detail in eAppendix 1 in Supplement 2, after initially being funded by the National Institutes of Health and the National Institute of Diabetes and Digestive and Kidney Diseases in 2012, additional funding was received to augment the trial, which involved, among other modifications, increasing the sample size from 400 to 600, and adding INS-30 as a second variable for interaction testing. With the larger sample size, the study had even greater statistical power, estimated at 90% based on post hoc calculations.
The main hypotheses addressed 12-month weight change by diet, diet and genotype, and diet and baseline INS-30. All hypotheses were addressed using generalized, linear mixedeffects models. 27, 28 We applied modified intent-to-treat principles. This means that all participants who were randomized and had baseline information were included in the analysis and analyzed according to original treatment assignment, regardless of adherence or loss to follow-up ( Figure 1 ). For the hypothesis about the effect of diet group on 12-month weight change, a linear mixed-effects model for weight that accounted for missing data under flexible assumptions regarding missingness was used with fixed effects for diet, time (baseline, 3, 6, and 12 months), and their interaction, along with a random effect for participant. For the hypotheses involving diet and genotype (or diet and baseline INS-30), an additional fixed effect was added for genotype (or baseline INS-30), along with all 2-and 3-way interactions (model appears in eAppendix 4 in Supplement 2).
The validity of such an analysis relies on the assumption that the missing outcome data measured at follow-up are unrelated to unobserved values of weight conditional on observed variables such as treatment assignment and baseline and intermittent values of weight. The hypothesis about diet was tested using a Wald test for the 2-way interaction between the 12-month time point and diet. The hypothesis about genotype (or baseline INS-30) was tested using a Wald test for the 3-way interaction between the 12-month time point, diet, and genotype (or baseline INS-30). Genotype was defined as matched for those participants with a 3-SNP combination suggesting success on a low-carbohydrate diet who were randomized to the low-carbohydrate diet, or for those participants with a 3-SNP combination suggesting success on a low-fat diet who were randomized to the low-fat diet. Genotype was otherwise defined as mismatched and is described in eAppendices 2and3inSupplement 2.
There were 185 individuals who were not classified as having either the low-fat genotype pattern or a low-carbohydrate genotype pattern (146 individuals with other 3-SNP patterns and 39 with missing or compromised genotyping data) who were excluded from the genotype analysis for the first hypothesis as originally planned. 10 An additional dietgenotype analysis was performed, restricting the study population to whites only and focusing on only 1 ancestry group as originally planned. 10 The second hypothesis was tested using a Wald test for the interaction among diet, 12-month time point, and baseline INS-30. The INS-30 variable was analyzed as a continuous variable, but is presented as tertiles for ease of presentation in parallel to the presentation of genotype pattern data. The cutoffs for the tertiles were determined using the baseline insulin concentrations of all 609 participants. A Satterthwaite approximation for denominator degrees of freedom was used in all Wald tests. 29 All tests were 2-sided and conducted at the .05 level of significance. Formal hypothesis testing was performed only for the 2 primary hypotheses. All other P values that were generated were purely descriptive in nature and correspond to secondary and exploratory analyses. Statistical analyses were performed using R version 3. Figure 1 . Baseline characteristics by diet group appear in Table 1 . Among participants in the healthy low-fat diet group, 130 (42.6%) had the low-fat genotype and 83 (27.2%) had the low-carbohydrate genotype, whereas in the healthy low-carbohydrate group, 114 (37.5%) had the low-fat genotype and 97 (31.9%) had the lowcarbohydrate genotype.
Of 22 assigned intervention instruction sessions for the full study sample, the mean number of sessions attended was 14.4 (SD, 5.3) for the healthy low-fat diet group and 14.6 (SD, 5.1) for the healthy low-carbohydrate diet group, which includes dropouts. Retention at 12 months, which was defined as participants who provided any data at 12 months, was 79% for both groups. Participant ratings for health educator enthusiasm and knowledge of material was high and similar between diet groups. The mean ratings were 4.6 to 5.0 on a scale of 1 to 5, with 5 as the highest rating.
Total energy intake was not different between diet groups at baseline or at any subsequent time point (P ≥.10for all; Table 2 ). Despite not being instructed to follow a specific energy (kilocalorie) intake restriction, the mean reported energy intake reduction relative to baseline was approximately 500 to 600 kcal/d for both groups at each time point after randomization.
At baseline, there were no significant between-group differences for any nutrients examined. In contrast, there were significant between-group differences after randomization at every time point (all P ≤ .001) for percentage of energy; intakes of carbohydrates, fat, protein, saturated fat, fiber, and added sugars; and glycemic index and glycemic load ( Table 2 ). In the healthy low-fat diet vs the healthy low-carbohydrate diet, respectively, the mean 12-month Fiber, g macronutrient distributions were 48% vs 30% for carbohydrates, 29% vs 45% for fat, and 21% vs 23% for protein.
Primary Outcome
The mean 12-month weight change was −5.3 kg (95% CI, −5.9 kg to −4.7 kg) for the healthy low-fat diet group and −6.0 kg (95% CI, −6.6 kg to −5.4 kg) for the healthy lowcarbohydrate diet group, which was not statistically different ( Table 3) . There was a similar range for weight change of approximately 40 kg within each group (−30 kg to 10 kg; eFigure 1 in Supplement 2).
Interaction Testing
The test for the interaction among diet, genotype pattern, and the 12-month time point was not statistically significant. The interpretation of the beta coefficient for the 3-way interaction (beta coefficient, 1.38 [95% CI, −0.72 to 3.49], P = .20) is that 12-month weight change increases (estimated as 1.38 kg) when switching from a healthy lowcarbohydrate diet and a low-carbohydrate genotype to a healthy low-fat diet and low-fat genotype beyond the main effects of switching from a healthy low-carbohydrate diet to a healthy low-fat diet and from a low-carbohydrate genotype to a low-fat genotype ( Figure 2A ). This indicates that there was no significant difference in weight change among participants matched vs mismatched to their diet assignment based on their 3-SNP genotype pattern. In analyses restricted to participants of European descent only, no significant interaction was observed by genotype pattern (the 3-way interaction for the main diet, genotype, and time yielded a beta coefficient of 2.58 [95% CI, −0.18 to 5.34];
Similarly, the test for interaction among diet, baseline insulin secretion (INS-30), and the 12-month time point was not statistically significant. The interpretation of the beta coefficient for the 3-way interaction (beta coefficient, 0.08 [95% CI, −0.13 to 0.28], P = .47) is that 12-month weight change increases (estimated as 0.08 kg) when switching from a healthy low-carbohydrate diet and x units of baseline INS-30 to a healthy low-fat diet and x + 10 units of baseline INS-30 beyond the effects of changing from a healthy lowcarbohydrate diet to a healthy low-fat diet and increasing baseline INS-30 by 10 μIU/mL ( Figure 2B ). Weight change trajectories for the diet-genotype pattern subgroups are presented in eFigure 2A and for diet and INS-30 tertile subgroups in eFigure 2B in Supplement 2. a Healthy low-fat diet minus healthy low-carbohydrate diet from linear mixed-effects model.
b Indicates ranking of foods according to the potential of 50 g of carbohydrates from that food to raise blood glucose relative to 50 g of glucose (scale of 0-100; a score of 100 refers to the same rate as glucose).
c Indicates the actual amount of carbohydrates multiplied by the glycemic index.
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Secondary Outcomes
There were improvements in the secondary outcomes for both diet groups. However, there were no significant between-group differences observed for body mass index, body fat percentage, and waist circumference (Table 3) . At 12 months relative to baseline, both diets improved lipid profiles and lowered blood pressure, insulin, and glucose levels, with the exception of low-density lipoprotein cholesterol concentrations, which increased for participants in the healthy low-carbohydrate group (Table 3 ). The 12-month changes in low-density lipoprotein cholesterol concentrations significantly favored a healthy low-fat diet. High-density lipoprotein cholesterol concentrations increased significantly more and concentrations of triglycerides decreased significantly more for the healthy low-carbohydrate diet group than for the healthy low-fat diet group. The decrease in the prevalence of the metabolic syndrome was not significantly different between the diet groups.
Respiratory exchange ratio was not significantly different between the groups at baseline, but was lower for the healthy low-carbohydrate diet group than for the healthy low-fat diet group at each time point after randomization (P < .001; eTable 1 in Supplement 2). Resting energy expenditure was not significantly different between groups at baseline or at 6 months or 12 months, but decreased significantly from baseline in both diet groups. Total energy expenditure was not significantly different between groups at baseline or any other time point. Relative to baseline, there was a small absolute mean increase in energy expenditure for both diet groups that was not significantly different than baseline.
Adverse Events
During the trial, there were 7 serious adverse events, all requiring hospitalization; 2 of these could have been related to the study (kidney stones and diverticulitis requiring surgery). There were 11 adverse events; 9 of these were related to the study or possibly related (eg, hypoglycemia following oral glucose tolerance test). Combined serious adverse events and adverse events were evenly distributed across the 2 diet groups.
Discussion
In this clinical trial of 609 generally healthy overweight or obese adults without diabetes who were randomly assigned to a healthy low-fat vs a healthy low-carbohydrate diet, there was no significant difference in weight loss at 12 months. In addition, there were no significant interactions between diet and 3 SNP multilocus genotype patterns or diet and baseline insulin secretion on 12-month weight loss. These results were observed in the context of similar mean 12-month weight loss in both diet groups that was greater than 5% of baseline body weight, and a similar and substantial range of weight change, reflecting approximately 40 kg within each diet group (from losing approximately 30 kg to gaining approximately 10 kg). Dietary intake of fats and carbohydrates was well differentiated between the 2 diet groups, as confirmed by diet 
No. of Participants
The black solid circle indicates the mean, the left and right borders of the box mark the first and third quartiles, the black vertical line indicates the median, the error bars indicate the 5th and 95th percentiles, and the hollow circles indicate the individuals whose values were outside the 5th or 95th percentiles. The No. of participants reflect data for the individuals who had weight data at both baseline and 12 months. Statistical analyses include data from all individuals randomized (described in the Statistical Analysis section).
A, Three-way interaction term among diet, genotype, and the 12-month time point was not statistically significant (beta coefficient, 1.38 [95% CI, −0.72 to 3.49]; P = .20). As described in Stanton et al, 10 of all the possible combinations of variance in 3 single-nucleotide polymorphism multilocus genotype patterns, some were considered consistent with the low-fat genotype pattern, some with the low-carbohydrate genotype pattern, and some with neither of these 2 genotype patterns. By design, as described in the initial National Institutes of Health grant application, those individuals with neither of the main 2 genotype patterns were not included in the main analyses. There were 39 participants who had compromised or missing DNA.
B, Three-way interaction term among diet, insulin, and the 12-month time point was not statistically significant (beta coefficient for 10-μIU/mL increase in insulin, 0.08 [95% CI, −0.13 to 0.28]; P = .47). Insulin-30 is the blood concentration of insulin 30 minutes after consuming 75 g of glucose as part of a standard oral glucose tolerance test. Insulin-30 was treated as a continuous variable in the statistical model. Tertiles were used in this Figure for ease of presentation. The mean for the lowest tertile was 40.8 μIU/mL (range, 7.3-60.6 μIU/mL); middle, 80.1 μIU/mL (range, 60.7-103.1 μIU/mL); and highest, 159.6 μIU/mL (range, 103.4-562.5 μIU/mL).
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Low-Fat vs Low-Carbohydrate Diet on Weight Loss in Overweight Adults assessment, and corroborated by changes in blood lipid parameters and respiratory exchange ratio, indicating strong treatment fidelity. With the large sample size, good retention, substantial weight loss and weight loss variability, and good adherence to and differentiation of diets, the study was well positioned to detect significant interactions by the primary variables of interest if they existed. However, no such effects were observed. Differences in weight loss between the 2 groups were nonsignificant and not clinically meaningful. Among the secondary outcomes, the clinical variables that were significantly different between the diet groups were the blood lipid results, which were more favorable in the healthy low-fat diet group for changes in low-density lipoprotein cholesterol and were more favorable in the healthy lowcarbohydrate diet group for changes in high-density lipoprotein cholesterol and triglycerides. The magnitude of the between-group differences were 5% for low-density lipoprotein cholesterol, 5% for high-density lipoprotein cholesterol, and 15% for triglycerides.
There is considerable scientific interest in identifying genetic variants that help explain interindividual differences in weight loss success in response to diet interventions, 31, 32 particularly diets with varying macronutrient compositions. The finding of no significant difference in weight loss in genotype-matched vs mismatched groups in the current study highlights the importance of conducting large, appropriately powered trials such as DIETFITS for validating early exploratory analyses. Analyses of all the genomic data obtained are under way to evaluate whether other genetic signatures may demonstrate effect modification.
Several research groups previously reported observing a differential effect of low-fat vs low-carbohydrate diets on weight loss by baseline insulin status. In both a 6-month feeding study with 32 participants and an 18-month freeliving study with 56 participants, effect modification between diet assignment (low-fat vs low-carbohydrate or low glycemic load) and INS-30 was reported. 12, 13 Using fasting insulin cutoffs in a 4-month feeding study involving 20 participants, Cornier et al 11 observed a significant diet × fasting insulin interaction for weight loss. A post hoc analysis from the A TO Z Study revealed a significant diet × fasting insulin interaction on 12-month weight loss among a subset of 81 overweight and obese women.
14 However, in a recent pilot study conducted in preparation for the DIETFITS study, a significant effect modification was not detected for INS-30 status. 35 In each case in which a significant interaction was reported, investigators proposed a mechanism involving insulin secretion status, insulin sensitivity, or insulin resistance interacting with glycemic load to differentially affect weight loss response with low-fat diets high in carbohydrates vs high-fat diets low in carbohydrates. 12, 36 In these studies, the consistent direction of the finding was that a lower carbohydrate diet was superior for those individuals with higher insulin secretion or higher insulin resistance; the putative mechanism involves a lower demand or burden on insulin-mediated glucose disposal for those with impaired insulin metabolism while maintaining a lower carbohydrate and higher fat diet. Despite mechanistic plausibility, studies to date have involved relatively small sample sizes.
Effect modification claims observed in single randomized trials are often spurious and this result is even more frequent when small sample sizes and post hoc analyses are involved; validation of such claims is infrequent.
37-39 The current study with a larger sample, a low-carbohydrate diet that was also a low glycemic load diet, and using INS-30 could not replicate findings from prior studies using smaller numbers of patients or those studies with a shorter duration. We consider the differences between the current findings and the studies cited to potentially involve diet quality beyond simply differentiating fat and carbohydrate intake. In this regard, refined grains are low in fat but considered of poor nutritional quality due to low-nutrient density relative to energy content. In contrast, vegetables are high in nutrient density, and relatively high in proportional carbohydrate content, but low in calories. Both diet groups in the current study were instructed to minimize or eliminate refined grains and added sugars and maximize intake of vegetables. We conclude that when equal emphasis is given to high dietary quality for both low-fat and lowcarbohydrate eating plans, it is not helpful to preferentially direct an individual with high insulin secretion status who is seeking weight loss to follow a lower-carbohydrate eating plan instead of a lower-fat eating plan. This study had several strengths. Study design strengths included the similarly intensive demands on both diet groups in making changes to baseline diets, similar focus on dietary quality, repeated major time points of data collection, and the extensive range of types of data collected. Strengths in study conduct included meeting and exceeding the sample size target of 600 participants, the nearly equal proportions of women and men enrolled, high and equivalent retention for both diet groups, and comparability of change between groups in potentially important outcomes related to weight loss, such as physical activity. In addition, the collective loss of approximately 3000 kg among study participants, and the wide individual variability of weight loss, provided the opportunity to meaningfully test for effect modification. 
Limitations
The study also has several limitations. First, generalizability of the findings may be limited by the conduct of the study in a geographic area with individuals who have attained relatively high education levels, and have personal resources and high accessibility to high-quality food options. To address this, the study was broadly advertised and successfully enrolled participants with relatively good ethnic and racial diversity, and a range, albeit limited, of educational attainment. Second, in regard to the possible role of insulin-glucose dynamics as an effect modifier in low-fat vs low-carbohydrate studies, there are many possible indices to consider other than INS-30, 36 a proxy measure of insulin secretion selected for reasons described elsewhere. 12, 13 But others have reported finding significant effect modification according to prestudy fasting insulin concentrations.
11,14
Third, there were 3 missing secondary anthropometric and metabolic variables (percentage of body fat, resting energy expenditure, and respiratory exchange ratio) for the first 78 participants enrolled in the study due to inadequate initial funding. This funding situation subsequently changed (described in eAppendix 1 in Supplement 2), which allowed the addition of these measurements for the remaining participants enrolled.
Fourth, the Stanford 7-day Physical Activity Recall tool (which was used to determine total energy expenditure) provides only a relatively crude assessment of total energy expenditure. Another method of measuring energy expenditure, such as the doubly labeled water method, would have provided greater accuracy; however, the overall cost and added participant burden were determined to be beyond the scope of the study. In addition, self-reported diet assessment methods are all known to have limited accuracy; therefore, we chose to use the Nutrition Data System for Research, which is recognized as a top method.
Fifth, even though insulin sensitivity was well assessed in this study, assessment of genetic characteristics as effect modifiers of diet response need better and increased study in the future because there has been much progress in understanding the genetic architecture of metabolic phenotypes such as obesity since the current trial was designed. Other explanations for heterogeneity besides insulin dynamics and genetic characteristics also need to be assessed.
Sixth, by not randomizing or conducting stratification according to genotype or insulin secretion status, the level of causal inference to be drawn from the analyses of interactions was limited; however, this allowed us to test for 2 primary interaction associations in the same study.
Conclusions
In this 12-month weight loss diet study, there was no significant difference in weight change between a healthy low-fat diet vs a healthy low-carbohydrate diet, and neither genotype pattern nor baseline insulin secretion was associated with the dietary effects on weight loss. In the context of these 2 common weight loss diet approaches, neither of the 2 hypothesized predisposing factors was helpful in identifying which diet was better for whom.
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Author Contributions: Dr Gardner had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. OBJECTIVE: The primary objective of this study is to confirm and expand on the preliminary results and determine if weight loss success can be increased if the dietary approach (Low Carb vs. Low Fat) is appropriately matched to an individualÕs genetic predisposition (LCG vs. LFG) toward those diets. This study will target both women and men (the A TO Z study involved only women), and address a set of specific aims intended to further elaborate on potential mechanisms and the clinical utility of these results. A new secondary aim has been added to this resubmitted application that will involve a rigorous exploratory investigation of additional SNPs that have shown genome-wide significant associations with obesity and metabolic phenotypes that might improve on the 3-SNP signature.
DESIGN:
The main study is a randomized trial employing a 2X2 parallel design to test the central hypothesis that there will be greater weight loss when 320 overweight/obese nondiabetic adults are matched vs. mismatched by genetic predisposition (LCG vs. LFG) to a 12-month Low Carb vs. Low Fat weight loss diet (n=80/cell). Participants will be genotyped prior to randomization, and blinding will be maintained for the genotyping results for both participants and data collectors during the study. Other than the primary outcome of weight change, which will be assessed monthly, primary data collection will occur at 0, 3, 6, and 12 months and include energy intake (3-day unannounced 24-hour recalls, NDS-R), appetite/satiety/hunger, energy expenditure (resting energy expenditure), body composition (DEXA), and blood variables (lipids, insulin, glucose, OGTT).
IMPACT: If the intriguing preliminary retrospective results are confirmed in this full scale study, the results will demonstrate that inexpensive DNA testing could help dieters predict whether they will have greater weight loss success on a Low Carb or a Low Fat diet. Commensurate with increasing scientific interest in personalized medicine approaches to intervention development, this would provide an example of the potentially substantial health impacts that could be obtained through understanding specific gene-environment interactions that have been anticipated from the unraveling of the human genome.
Specific objectives or hypotheses;
Specific Aim #1 Ð Determine, using an experimental design, if matching vs. mismatching overweight women and men to a Low Carb or a Low Fat weight loss diet based on their
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predetermined genotype pattern (LCG vs. LFG) has a significant and differential impact on 12-month weight loss.
Specific Aim #2 Ð Explore whether additional gene variants that are robustly associated with obesity or related metabolic phenotypes may improve upon the LCG/LFG prediction of the optimal response to Low Carb vs. Low Fat weight loss diets.
Specific Aim #3 Ð Examine putative mechanisms that could explain differential weight loss success (e.g., energy intake, appetite/satiety/hunger, energy expenditure, insulin/glucose homeostasis).
Description of trial design including allocation ratio;
Parallel design 12-month protocol Randomly assigned 50:50 to Low-Fat vs. Low-Carb weight loss diets
Eligibility and exclusion criteria for participants;
Participants will be recruited from the local community primarily through media advertisements. Pre-menopausal women and men ages 18-50 years will be invited to enroll if BMI is 27-40 kg/m 2 , body weight is stable over the previous 2 months, and medications are stable for ≥ 3 months. Potential participants will be excluded if they self-reported: hypertension, type I or II diabetes mellitus, heart, renal, or liver disease, cancer or active neoplasms, hyperthyroidism unless treated and under control, taking any medications known to affect weight/energy expenditure, blood pressure, or blood lipids, smoking, alcohol intake ≥ 3 drinks/day, pregnancy, lactation, no menstruation for the previous 12 months, or plans to become pregnant within the next year.
Interventions for each group with sufficient details to allow replication, including how and when they are going to be administered;
The intervention will be a class-based education program led by two health educators (HEs). Participants will be assigned to groups of 15-20 per class to follow either a Low-Fat or Low-Carb diet. There will be 22 one-hour classes over 12 months; once/week for 8 weeks, then once every other week for 8 weeks, then once every third week for 8 weeks, and then finally once/month for the last 6 months of the protocol. The focus of the first 8 classes will be on strategies for dramatically lowering total grams of fat or carbohydrate, depending on diet assignment. From the 9 th week through 6 months the focus will be on similar topics for both diet groups Ð holiday eating, family member situations Ð both supportive and unsupportive, deviations from adherence and strategies for getting back on track, and much more. For the last 6 months of the study most of the topics will involve identifying and addressing any barriers to making these long-term and lasting dietary changes.
Dietary strategy. There will be four central components to the dietary strategy. The first is ÒHow Low Can You GoÓ (Limbo). Low-Fat participants will be instructed to cut back to 20 grams/day of total fat, and for Low-Carb to 20 grams/day of digestible carbohydrate. The goal is to achieve the lowest level of fat or carbohydrate intake within the first eight weeks. The second stage (Titrate) is to slowly add fat or carbohydrate back to the diet in increments of five grams/day (e.g., from 20 to 25 grams/day) and then hold it at that amount for 1-4 weeks before adding another 5 grams/day. The third component is to identify the lowest level of fat or carbohydrate intake participants feel could be maintained long term, potentially for the rest of their lives. The fourth strategy is to promote high nutrient density (Quality). Other Quality concepts included Òreal food,Ó Òminimally processed,Ó Òseasonal,Ó Òorganic,Ó Ògrass-fed,Ó Òwhole grain,Ó and Òpasture-raised,Ó depending on diet assignment. Both diet groups will receive similar instructions to drink water and to minimize added sugars, refined white flour products, and sources of trans fats. All participants will be encouraged to take an active role in making food choices; by preparing their own foods at home, reading labels, and asking for appropriate modifications for restaurant menu items.
In summary, the diet strategy for both Low-Fat and Low-Carb is a ÒLimbo-Titrate-QualityÓ approach designed to motivate participants to achieve the lowest possible level of fat or carbohydrate intake with maximal overall nutritional quality and a dietary pattern that could be continued for a lifetime.
Beyond fat and carbohydrate lowering. Notably, there are no calorie restriction targets in the intervention. Participants will be encouraged to track their intake using daily food journals and computer tracking programs. While the first 8 weeks of classes focused specifically on separate strategies to lower fat or carbohydrate intake, the subsequent four months of classes addressed more global topics for both diet groups, similarly, such as mindful eating, adequate sleep, body acceptance, and sugar addition.
Completely defined pre-specified primary and secondary outcome measures,
Primary outcome is weight change (likely to be looked at as 12m change in BMI, but will also calculate the trajectory of the combined 3m, 6m and 12m difference from baseline).
Secondary outcomes include:
Insulin resistance (assessed by repeated OGTTs) Lipid profile Percent body fat (as assessed by DXA) Blood Pressure Cytokines
Description of the similarity of interventions, if relevant;
¥ Both diet groups will meet for the same number of classes Ð 22 over the course of a year. ¥ Both diet groups will be encouraged to be physically active, and to meet or exceed national standards for physical activity. ¥ Both groups will be told that there is no specific calorie restriction involved, but they are allowed to choose this and follow it themselves if they want to. ¥ Both groups will be given initial diet goals of decreasing current fat or carbohydrate intake to 20 grams/day, which we consider to be comparably ambitious.
Settings and locations where the data are to be collected;
All settings and locations are on the Stanford University campus (i.e., single site trial).
Data collection:
1070 Arastradero Road: DEXA, self-reported weight, and some others collected at 1070 Arastradero Rroad, the human Description of how sample size will be determined, including statistical power analysis and a predetermined stopping point;
Sample Size/Power Calculations. Based on our previous experience conducting weight loss trials of this length, for the primary analysis (Aim 1) we will assume an attrition rate of ~20% among the n=320 randomized in the study; we expect ~260 participants will complete the study and be included in the complete case analysis. With 260 participants we will have more than 95% power to detect differences of 1 unit change in BMI (~6.5 lbs, or ~3 kg) between the appropriate and inappropriate groups in our primary aim (i.e., a moderate effect size of 0.5). This is based on a two-sided t-test, assumes a type I error rate of 0.05, and a standard deviation of 12 month weight change of 2 BMI units (~13 lbs). The sample size for the secondary analysis (aim 2) will be slightly higher since all participants are included without consideration of the 3-locus genotype (n=400 of which about 320 should have complete follow-up), but given the exploratory nature, we will not make any strong inferences at alpha=0.05; instead, these analyses will only be seen as a first selection screen for choosing/prioritizing additional markers for future study.
No stopping point.
Description of statistical methods to be used to compare groups for primary and secondary outcomes (t-tests of group means, permutation tests, intent-to-treat analysis, using randomization as an instrumental variable to recover the local average treatment effect, etc.);
Primary analysis will test the hypothesis that there is a diet X genotype interaction for weight loss.
STATISTICAL ANALYSES
Preliminary Checking of Data and Underlying Assumptions. Descriptive statistics such as means, medians, standard deviations, and interquartile ranges will be generated for all continuous variables, while frequency distributions will be provided for discrete and categorical variables. Graphical tools such as histograms and QQ-plots will be used to assess distributional properties of continuous variables. In cases where nonnormality is suspected, a transformation of the outcome or a non-parametric approach may be considered. We will also evaluate whether, despite the randomization procedure, baseline variables differ between the 2 intervention arms and the genotype strata and adjust for those variables where significant differences are observed. Finally, where possible, we will describe differences between those with missing and observed data on key variables.
Plan of Analyses
Primary Analysis. The primary analysis will address Specific Aim 1. Using 12-month weight change as the primary outcome, we will assess whether there are differences in weight change between those appropriately assigned to intervention group or not using the information from the LCG and LFG strata. Regression techniques such as ANOVA will be used to estimate differences between groups (both with and without adjustment for baseline characteristics).
Secondary Analyses. The secondary analyses will address Specific Aim 2. Using 12-month weight change as the outcome, we will use group lasso methods to assess whether additional SNPs are predictive of weight change and/or can improve upon the ability of the multi-locus genotype pattern to predict weight change. The additional SNPs we will consider are those that have been previously robustly documented to have genome-wide significant association with weight, waist circumference or metabolic phenotypes (lipid levels, type 2 diabetes, insulin resistance) in previous studies. The list of genes will be compiled based on the latest update of the Catalog of Genome-Wide Association studies, which is continuously updated by NHGRI18, 93 and will include all independent genetic variants with corresponding p-values smaller than 5x10-8 for any of these phenotypes. These are only exploratory analyses and will only serve to identify additional potential gene loci that may regulate response to specific diets and should be studied in further, larger studies in the future. There are currently almost 200 such independent genetic variants that have been discovered and we anticipate that approximately 250 or more may be available in the next year or so. The group lasso approach is more sophisticated than one that assesses each SNP alone. First, it avoids the multiple comparison issue involved with testing 200-250 hypotheses. Second, we expect some degree of correlation among the SNPs and are particularly interested in whether we can enhance the predictive ability of the previously identified genotype pattern with additional SNP information. We therefore would like to jointly consider or incorporate additional SNP information. Group lasso improves upon the SNP-by-SNP approach by jointly penalizing regressions so that overfitting is minimized. The variables considered will be diet assignment, each SNP, and its interaction with diet assignment. Those SNPs (and possibly their interactions with diet assignment) that are exceptionally useful for predicting 12-month weight change will be identified. The use of cross-validation to select the penalization parameter assures us that the model will not be overfit to the data. The sparsity of the coefficients makes the results easier to interpret. The SNPs and their interactions with diet that have the largest non-zero coefficients would be identified as the most important factors in a parsimonious description of the association. This analysis will thus reveal whether some group of SNPs & their interaction with diet assignment accounts for a significant portion of the variability in weight change. A further critical step (assuming the 3-locus genotype is found to be an important predictor in Aim 1) will then be to evaluate the contribution of the newly identified SNPs (expressed as a weighted linear combination or score as informed by group lasso) in predicting weight change in the presence of the multi-locus genotype pattern. Using crossvalidation methods, we will assess whether the prediction error corresponding to a model with the multi-locus genotype, diet and their interaction that additionally includes the newly derived score identified by the group lasso method is significantly lower than the error resulting from a model that only includes the multi-locus genotype, diet assignment and their interaction.
The objective of Aim 3 is to provide further insight into possible mechanisms of action by identifying potential mediators of the relation between weight loss and appropriate assignment. For this purpose we will use contemporary mediation analysis techniques.136-138 Selected mediators for these analyses will focus on energy balance: energy intake (Kcal/day, appetite, satiety, hunger), and energy expenditure (resting energy expenditure, physical activity), and on insulin sensitivity/resistance.
Missing Data, Drop-Outs, and Intent-to-Treat. Analyses that do not account for missing data can lead to biased and inefficient estimates. To address such issues, we will perform both a complete-case analysis that excludes individuals missing at least one variable in the model as well as a multiple imputation-based model. Multiple imputation provides statistically valid results when the data are missing at random (i.e., the reason for missingness is related to observed variables only).139 Although the data may not be missing at random (e.g., if people who lose less weight are more likely to drop out), conditioning on baseline weight and/or subsequent weight measurements available make the missing at random assumption more reasonable. We will compare results from both strategies as a sensitivity analysis. Regardless of the level of dietary adherence to the intervention diets, we will analyze data collected from all randomized subjects and consider randomized intervention group as the intervention assignment, in accordance with intent-to-treat principles.
Explanation of any interim analyses that might be planned, when applicable;
None.
Description of the method used to generate the random allocation sequence;
Random assignments will be generated using the blockrand function from the blockrand package in R.
Specification of the type of randomization, such as blocked or paired, details of any restriction (such as blocking and block size) and disclosure and explanation if eAppendix 1. Chronology of funding for DIETFITS -increased sample size, additional primary analysis Overview This document is intended to summarize the impact on our study when an additional $5M became available in September 2013 to augment the $3.2M from NIH/NIDDK received in August 2012. Main impacts relevant to changes to CT.GOV include:  Original projected sample size of n=400 was increased to n=600 (actual enrollment was n=609)  Original population of Caucasian-only was expanded to all races/ethnicities  An additional primary analysis was incorporated into the main objectives -insulin secretion (INS-30). 2. Decision to not stratify randomization by genotype pattern. After discussions with several expert colleagues, we decided to not stratify randomization based on genotype due to the ever-evolving nature of genetic/GWAS studies that might have shown the trial to be obsolete before completion. Randomizing on the initial 3-SNP genotype pattern would limit the use of the rich data set collected as part of the study and the ability to use this to continue investigation into which factors might modify weight loss on these diets. Given the existing data that suggested a ~40:40:20 distribution of LFG, LCG and NEITHER-Genotype, it was anticipated that adequate representation of the two main genotypes -LFG and LCG -would be achieved in both diet groups through straight randomization to the two diet groups, without stratification. Adequate representation would allow for the original 2X2 analysis to be conducted.
NIH/NIDDK
Approached by the Nutrition Science Initiative (NuSI).
In the fall of 2012, just after being funded by NIH, we were approached by the newly founded NuSI group with an extraordinary offer to provide an initial $3M in unrestricted funds to augment the study if we could also raise a matching $2M in unrestricted funds from donors within an 8-month time frame (January 1-August 31, 2013); i.e., a total augmentation of $5M to the initial $3.2 from NIH.
The primary request from NuSI was to make the study more rigorous and more impactful. The specific factors agreed on were to make the study larger (more participants) and more extensive (more secondary and exploratory outcomes measures) without extending the timeline (faster pace of enrollment).
We prioritized: a. Increasing sample size from n=400 to n=600. b. Opening inclusion criteria to all race/ethnic groups (projecting that ~2/3 of the 600 would be Caucasian (n=400), and thus not compromising the original plan to recruit 400 Caucasians) c. Adding a second primary effect modifier -insulin resistance (which we chose to assess as insulin secretion, INS-30, as described elsewhere)
5. Communication/documentation of these changes. IRB changes were made noting larger sample size and added measurements starting in 2013. The NIH Project Officer for this grant, Robert Karp, was told of the randomization plan during a visit to Stanford in June 2014, and he expressed concurrence.
On October 12, 2015 we changed the CT.GOV to note that the primary analyses would now include a second effect modifier -insulin resistance.
In August of 2016 we submitted a Methods and Design manuscript to Contemporary Clinical Trials describing the changes described above (accepted and available on-line in December 2016)
These decisions had been made and were in place prior to unblinding the randomization assignment and prior to doing any of the statistical analyses.
Using insulin secretion, rather than a proxy measure of insulin resistance.
In a pilot study for the current DIETFITS study (Gardner et al., Obesity, 2016;24:79-86), we had used INS-AUC (area-under-the-curve of insulin concentrations at 0, 30, 60 and 120 minutes from an Oral Glucose Tolerance Test, OGTT) as a proxy measure of insulin resistance. We had planned to use the same measure in the main analysis in DIETFITS. Prior to running any analyses, we discussed different possible related measures available from the OGTT, and it was decided that insulin secretion (INS-30) would be superior. INS-30 was used in the primary analysis. This is described in the main part of this paper.
SUMMARY
For the reasons described above:
a. Randomization was not stratified -it was a straight randomization to the two diet groups b. With n=600, the study was adequately powered to test two distinct potential effect modifiers -INS-30 and Genotype Pattern.
c. % Body Fat, REE and RER are missing at baseline for ~n=80 participants due to the events described above.
This can be challenging to communicate efficiently in the main manuscript. The original NIH application, the original CT.GOV registration, and the original IRB documentation all suggest a smaller sample size (n=400), with only one primary effect modifier (Genotype Pattern).
The two joint primary analyses were informed by the literature, including our own previous research. The randomization was not unblinded and no analyses were conducted, until the study and all data cleanup were completed.
eAppendix 2. Additional details on genotype assessment
The UK Biobank Axiom® Array was used for genome-wide genotyping in all participants. DNA samples with a genome-wide genotyping success rate of <95%, duplicate discordance or sex mismatch, genetic ancestry outliers (as determined by cluster analysis performed via principal-component analysis), SNPs with a genotyping success rate of <95%, monomorphic SNPs, SNPs with minor-allele frequency (MAF) <1%, and SNPs that mapped to several genomic locations were removed from the analyses. A total of 538959 UK Biobank SNPs were used for genotype imputation.
Imputation was performed on the Michigan Imputation Server (https://imputationserver.sph.umich.edu/index.html ) using the reference panel released by the Haplotype Reference Consortium ( http://www.haplotype-referenceconsortium.org/ ). The variant rs1799883 was well imputed, with an imputation quality score ( r 2 ) of 0.991. Although many specific gene variations have been associated with obesity and obesity related phenotypes, [1] [2] [3] [4] [5] only a small number of variations have been reported to have an effect on short-term weight loss in hypocaloric dietary intervention studies. [6] [7] [8] [9] We are aware of only one study (10 weeks) that compared low carbohydrate and low fat diets and observed a genotype-diet interaction effect on weight loss. 10 Although gene variations that are associated with obesity should be relevant to weight loss, the translation into actionable information for more successful weight management is challenging. [11] [12] [13] We specifically focused on functional gene variations that had evidence of interactions with either dietary carbohydrate or fat relative to weight loss, and used the biological effect 12 of each allele to develop multi-locus genotype patterns that grouped all individuals by likelihood of being more carbohydrate sensitive, more fat sensitive, or a mixture of both (i.e., neither low carb or low fat). These genotype patterns were developed prior to the start of the study, 14 and the primary objective of the study was to explicitly assess the ability of the predetermined genetic patterns to predict improved weight loss relative to macronutrient content of the diet.
Lowering carbohydrates achieved better weight loss in subjects with the LCG pattern. This is consistent with evidence on biological effects attributable to allele G (12Ala) at the PPARG locus and allele G (27Glu) at the ADRB2 locus, that together constitute the LCG pattern. PPAR protein regulates adipocyte formation and function, and the PPARG-12Ala genetic variant reduces DNA binding and activation of target genes. 15 Although not all studies agree on effects of PPARG variants, in general most studies report a strong diet-genotype interaction relative to body composition, with individuals carrying the 12Ala variant, i.e. allele G, being less sensitive to fat levels [16] [17] [18] and more likely than those with genotype C/C (12Pro/Pro) to be obese if their habitual carbohydrate intake exceeds 49% of energy. 19 In addition, women with the 12Ala variant regained more weight after a six month hypocaloric diet and had greater carbohydrate oxidation and less fat oxidation than those without the variant. 20 The LCG findings in the current study are also consistent with reports for individuals carrying ADRB2 allele G. The -adrenergic receptors are involved in adipocyte lipid mobilization in response to catecholamines, and the ADRB2-27Gln/Glu polymorphism has been associated with obesity and altered adipocyte -adrenergic receptor function. [21] [22] [23] In a crosssectional study, women carrying the ADRB2 allele G (27Glu) who consumed above the median of 49% calories from carbohydrates had an increased risk for obesity and increased insulin levels compared to women who did not carry the genetic variant. 24 The improved weight loss observed by lowering fat in subjects who were classified as an LFG pattern is consistent with previously reported biological effects attributable to carriage of allele A (54Thr) at the FABP2 locus and genotype C/C (Pro12Pro) at the PPARG locus, that together constitute the LFG pattern. The FABP2 allele A codes for a variant in the amino acid sequence (54Thr) of intestinal fatty acid binding protein 2 that is prominent in enterocytes. The variant has a two-fold greater binding affinity for long-chain fatty acids 25 and enhanced fat absorption and/or processing of dietary fatty acids by the intestine. 26 Multiple studies have shown that individuals with the FABP2-54Thr polymorphism respond differently to dietary fat compared to those without the polymorphism, including higher levels of non-esterified fatty acids after a high-fat meal, 27 increased postprandial levels of triglycerides, 28 glucose, and lipogenesis. 29 The PPARG allele G codes for an altered protein (12Ala) variant that has decreased binding affinity of the PPAR with its response element and decreased PPAR activity. 15 In addition, in adipocyte cell models, the 12Pro protein had increased adipocyte differentiation compared to the 12Ala variant. 30 Individuals with the PPARG genotype C/C (12Pro/Pro), a component of the LFG, display increased adiposity and higher BMI and waist circumference in the presence of high total fat intake and may be more resistant to weight loss compared to those carrying the 12Ala variant. 16, 17, 31 Some gene variants associated with obesity, including those evaluated in this study, have been associated with disruption of pathways involved in energy intake and satiety 32 Examples include higher food intake in individuals carrying the FABP2-54Thr vs. FABP2-54Ala form of the protein, 33 compensatory eating behaviors in individuals with variants of PPARG and ADRB3 genes, 34 and higher satiety in individuals with the PPARG (12Pro/*) and ADRB2 (27Glu/*) variants compared to those in the PPARG (Pro12Pro) and ADRB2 (Gln27Gln) group. 35 These findings are consistent with the observed trend toward lower reported daily Kcal intake among those assigned to a diet matched to their genotype pattern in the current study. 
